Table of Contents
This report considers the diagnostic promise of non-coding RNA molecules, with a particular focus on the microRNAs. miRNAs (MicroRNAs) are short, single stranded RNAs that regulate mRNA expression at the post-transcriptional level. These small bits of RNA, members of a class of non-translated molecules that do not produce protein, shut off gene transcription by base pairing with the target molecules. They are now recognized as pivotal regulators of gene expression; including development, proliferation, differentiation, and apoptosis and serving widespread functions as regulatory molecules in post-transcriptional gene silencing. As the report details, a large number of companies, both small biotechs and big pharmaceutical companies are committed to miRNA diagnostics.
As part of its coverage of this topic, this report includes the following:
Overview of miRNAs
Positive Factors for miRNA Diagnostic Technologies
miRNAs and Neurological Disorders
miRNA and Metastatic Brain Lesions
Prostate Cancer Screening and miRNAs
miRNAs and Resistance to Anti-Cancer Drugs
Discussion of Patent Issues
Interviews with Industry Experts
One the positive side of the equation, the technology is innovative, and offers the promise of non-invasive diagnostics for cancer and other disorders that could be cheaper, faster and more accurate than existing tests, which are either non-existent or leave much to be desired. On the negative side of the equation, there are many complex challenges that must be resolved before the technology can be applicable. There is a need for large scale clinical trials, and rigorous standardization of the assay conditions, given the fact that the assessments of serum levels of miRNA molecules are quantitative. This report considers the potential for the miRNA market in research and diagnostics and the challenges. In doing so, the report looks at several companies currently developing research and diagnostic miRNA technologies.
As part of its coverage, the miRNA offerings and products in developments in the following companies are profiled in detail.
Eisai Biomarkers and Personalized Medicine
Genomic Health Inc.
GlaxoSmithKline Discovery and Molecular Toxicology
Groove Biopharma (formerly Mirina)
Hologic-Gen Probe Inc.
Mello Biotechnology Inc.
Pacific Edge Biotechnology
Santaris Pharma A/S
Diagnostics: Small RNA Assays and Biomarker Validation
Tekmira Pharmaceuticals Corporation
Thermo Fisher Scientific, Inc.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
Global Non-alcoholic Steatohepatitis Biomarker Market: Overview Non-alcoholic steatohepatitis (NASH) is liver disease which is categorized under the spectrum of non-alcoholic fatty liver disease (NAFLD). ...
The global biomarkers market is estimated to reach USD 53.34 billion by 2021 from USD 27.95 billion in 2016, at a CAGR of 13.8% from 2016 to 2021. Increasing diagnostic applications of biomarkers, increasing ...
The global next-generation sequencing market is estimated to register a CAGR of 20.5% from 2017 to 2022 to reach USD 12.45 billion by 2022. Factors such as technological advancements in NGS platforms, ...